New: NCI-funded clinical trial search
Mednet Logo
CommunityHematology

Hematology

Clinical discussions on blood disorders, coagulation, transfusion medicine, and hematologic malignancies.

Recent Discussions

Would you avoid giving an IMiD in the context of newly diagnosed multiple myeloma with a recent diagnosis of a serious solid tumor like pancreatic cancer?

1 Answers

Mednet MemberInvited Expert
Medical Oncology · Harvard Medical School

Doing just a PI and antibody-based treatment would be totally reasonable. Adding an IMiD in the future, depending on how their treatment is going; one can always consider an IMiD or a cell mod later. I don't believe, though, that the addition of an IMiD will increase the risk of Ca progression. It i...

When do you pursue MRI iron quantification for elevated ferritin with normal TSat, and when do you consider rare diagnoses like ferroportin disease or aceruloplasminemia?

1 Answers

Mednet MemberInvited Expert
Pediatric Hematology/Oncology · Weill Cornell Medical College

Serum ferritin is an acute-phase reactant, so it can often be elevated without true iron overload, especially in the setting of viral illnesses or other inflammatory events. It is best not to do the test when something like that has occurred in the past 3-4 weeks or so. Overnight fasting is key to t...

How have the results of the SUNMO trial with mosunetuzumab/polatuzumab vedotin impacted your treatment choices for transplant ineligible relapsed/refractory DLBCL?

2 Answers

Mednet Member
Medical Oncology · IHA Hem Onc Consult

Mosunetuzumab/polatuzumab is an effective salvage regimen for patients with R/R DLBCL (ORR 70%, CR 51%, and PFS 11.5 months) with a manageable toxicity profile. This, and other bispecific combinations, address the short PFS associated with single-agent bispecific antibody use. It is endorsed by the ...

About Mednet

A community where doctors find answers to medicine's toughest questions.

  • Verified, credentialed physicians
  • 45,000+ members across 24 specialties
  • Free CME and MOC credit

Can RT to non-bulky sites be omitted in an early stage (stage I or II) classical Hodgkin's lymphoma case with a CR by PET/CT?

4
1 Answers

Mednet MemberInvited Expert
Radiation Oncology · Duke University Medical Center

Randomized studies have consistently demonstrated that combined modality therapy is superior to chemotherapy alone in regards to progression-free survival in early-stage Hodgkin lymphoma. The magnitude of the benefit varies across studies, but a relative risk reduction of ~50% can be expected which ...

How do you manage patients with atrial fibrillation having a thromboembolic infarct despite being on adequate anticoagulation?

11
4 Answers

Mednet MemberInvited Expert
Neurology · HCA Houston Healthcare

This scenario is always challenging. In terms of anticoagulation, the efficacy of DOACs in preventing embolic events in AF patients is around 70%, which is impressive compared to warfarin but not foolproof. In cases of a second embolic event while on anticoagulation, two reasonable approaches are of...

How soon after initiating oral anticoagulation therapy for atrial fibrillation can it be interrupted for surgery or procedures?

2
1 Answers

Mednet MemberInvited Expert
Cardiology · Ohio State University Cardiovascular Medicine

As with most things medical, multiple answers. If a patient walks into my office for preOp "clearance" and behold, they are in atrial fib, but asymptomatic, then it would depend on the urgency of their surgery. If elective, then you have time to work up his atrial fib and look for a reversal cause (...

For patients with VEXAS syndrome and good response to azacitidine, what duration of therapy do you consider?

4
1 Answers

Mednet MemberInvited Expert
Hematology · Dalhousie University, Canada

The short answer: as long as azacitidine is controlling inflammation, reducing/eliminating steroid dependence, and/or improving cytopenias, keep using it. Don't stop (or if the patient is being bridged to alloSCT, continue until BMT).The long answer:VEXAS is an autoinflammatory disease wherein patie...

How do you decide whether to use pharmacologic VTE prophylaxis in hospitalized patients with decompensated cirrhosis?

2
3 Answers

Mednet MemberInvited Expert
Hospital Medicine · University of Wisconsin Health University Hospital

For all patients, I begin by using a standard risk prediction tool to determine if the patient is appropriate for pharmacologic VTE prophylaxis. At our institution, the Padua risk prediction tool is embedded in our electronic health record/admission set. Clinical guidelines- including those from the...

How do you counsel patients on the risk of clinically relevant bleeding or other complications with bone marrow aspiration and biopsy?

2 Answers

Mednet MemberInvited Expert
Hematology · Beth Israel Deaconess Medical Center

I counsel patients that, in general, bone marrow biopsies are a fairly safe procedure from a bleeding standpoint due to minimal tissue between the skin and the bone, and the superficial nature of the biopsy, such that if there is bleeding, pressure can be applied. That said, this depends on the abil...

How, if at all, should a positive thrombophilia result influence the duration of anticoagulation following a first VTE provoked by a transient risk factor?

2
1 Answers

Mednet MemberInvited Expert
Hematology · Medical University of South Carolina

The answer depends on how we characterize a “transient” risk factor. The “provoked” vs “unprovoked” approach to the duration of anticoagulation rests on the assumption that, in patients with VTE, anticoagulation should continue until the risk of recurrence declines to the baseline level seen in the ...